Skip to content

Advertisement

  • Research
  • Open Access

The influence of N-acetyl-L-cystein infusion on cytokine levels and gastric intramucosal pH during severe sepsis

Critical Care20048:R172

https://doi.org/10.1186/cc2866

  • Received: 23 December 2003
  • Accepted: 20 April 2004
  • Published:

The Erratum to this article has been published in Critical Care 2016 20:403

Abstract

Introduction

The purpose of the present study was to evaluate the effects of continuously infused N-acetyl-L-cystein (NAC) on serum cytokine levels and gastric intramucosal pH in humans suffering from severe sepsis.

Methods

Fifty-three patients were included in the study. In the NAC group (n = 27), after an initial intravenous bolus of NAC (150 mg/kg over 5 min), a continuous intravenous infusion of 12.5 mg/kg per hour was given for 6 hours. Patients in the control group (n = 26) were administered dextrose (5% solution) at the same dosage. We recorded the following: haemodynamic parameters, nasopharyngeal temperature, arterial blood gas changes, plasma cytokine levels, biochemical parameters, intramucosal pH, length of stay in the intensive care unit, duration of of mechanical ventilation and mortality. All measurements were taken at baseline (15 min before the start of the study) and were repeated immediately after the bolus infusion, and at 24 and 48 hours after initiation of the continuous NAC infusion.

Results

No differences were found between groups in levels of the major cytokines, duration of ventilation and intensive care unit stay, gastric intramucosal pH and arterial oxygen tension/inspired fractional oxygen ratio (P > 0.05).

Conclusion

We found that NAC infusion at the doses given did not affect cytokine levels, outcomes, or gastric intramucosal pH in patients with severe sepsis. Because of the limited number of patients included in the study and the short period of observation, our findings need confirmation in larger clinical trials of NAC infused in a dose-titrated manner. However, our results do not support the use of NAC in patients with severe sepsis.

Keywords

  • cytokine levels
  • gastric intramucosal pH
  • haemodynamic parameters
  • intensive care unit
  • N-acetyl-L-cystein
  • severe sepsis

Introduction

Sepsis is defined as the systemic response to infection [1, 2]. The deleterious effects of invasion of body tissues by bacteria result from the combined actions of enzymes and toxins, produced both by the micro-organisms themselves and by endogenous cells in response to the infection. Patients with severe infections have extremely low concentrations of protective antioxidants and high levels of the metabolic products of free radical damage, with the greatest increases seen in the most severely ill [3, 4].

N-acetyl-L-cysteine (NAC), a derivative of the naturally occurring amino acid L-cysteine, is currently indicated for acute paracetamol overdose [5]. Pharmacological actions include repletion of intracellular glutathione stores, scavenging of toxic oxygen free radicals (both directly and indirectly via increased glutathione concentrations) and suppression of tumour necrosis factor (TNF) production [6]. NAC may also exert a beneficial effect on the oxidation and downregulation of essential thiol groups in β-adrenergic receptors [7]. Furthermore, NAC has been shown to decrease lipoperoxidative damage in early clinical septic shock [8].

Gastric intramucosal pH (pHi) in experimental animals decreases as splanchnic perfusion decreases below the level at which local oxygen transport can no longer sustain aerobic energy production [9]. Therefore, it may be possible to use pHi as an early and noninvasive index of systemic tissue oxygenation, given that selective reductions in splanchnic perfusion occur with decreases in systemic oxygen transport [9].

The purpose of the present study was to evaluate the effects of continuously infused NAC on serum cytokine levels and pHi in humans suffering from severe sepsis.

Methods

Patient population and study design

The Regional Committee on Medical Research Ethics approved the study. Written informed consent was obtained from patients (wherever possible) or from the next of kin. Critically ill patients with bacteriologically documented infections were included in the study as soon as they met at least two of the following criteria for sepsis, as defined by the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee [2]: temperature >38°C or <36°C; heart rate >90 beats/min; respiratory rate >20 breaths/min or arterial carbon dioxide tension <32 mmHg; and leucocyte count >12 × 109 cells/l or <4 × 109 cells/l. In addition, at least one of following conditions was required: hypoxaemia (arterial oxygen tension/fractional inspired oxygen ratio <250); oliguria (urine output <0.5 ml/kg body weight for 2 hours); lactic acidosis (lactate concentration >2 mmol/l); thrombocytopenia (platelet count of <100 × 109/l); or a recent change in mental status without sedation. Patients who were under 18 years old, pregnant, or receiving corticosteroids, immunosuppressants, or chemotherapy, and those with a known irreversible underlying disease, such as end-stage neoplasm, were excluded.

The Acute Physiology and Chronic Health Evaluation II [10] and Sepsis-related (or Sequential) Organ Failure Assessment [11] scores were employed to determine the initial severity of illness. If required, patients underwent surgical procedures before the start of the study. No invasive surgery was performed during the 48-hour study period. All patients were ventilated in volume-controlled mode (Puritan Bennett 7200; Puritan Bennett Inc., Carlsbad, CA, USA) and received continuous analgesic sedation with midazolam and fentanyl. Ventilator settings, and levels of positive end-expiratory pressure and fractional inspired oxygen were kept constant during NAC or placebo infusion. Antibiotic treatment was adjusted according to the results of bacteriological culture (blood or or other samples). In all patients fluid replacement was administered to keep the central venous pressure between 4 and 8 mmHg. No inotropic agent was administered during the study. Those patients who met the above criteria for severe sepsis were enrolled in the study within 4 hours of intensive care unit (ICU) admission.

Protocol

Randomization was done using a computer-steered permutated block design. The study was prospective, randomized, double blind and placebo controlled. In order to perform the study in a double-blind manner, drug solution and infusion was administered to all patients by a nurse without any knowledge about the study protocol. Follow up was done by an anaesthetist without any knowledge of the study protocol. Patients in the NAC group (n = 27) were given NAC (ASIST®; Istanbul, Turkey; 300 mg/3 ml, 10%) as an intravenous bolus of 150 mg/kg over 30 min, and then as a continuous intravenous infusion of 12.5 mg/kg per hour for 6 hours. In the control group (n = 26), patients were given 5% dextrose as bolus and infusion over 6 hours (same dosage).

A tonometer (TRIP NGS Catheter; Tonometrics Inc., Worchester, MA, USA) was inserted via the nasogastric route before infusion of the bolus. The tonometer was advanced until the balloon was located in the lumen of the stomach. The position of the balloon was confirmed radiographically. The silicone balloon of the tonometer was filled with 2.5 ml 0.9% saline. After sufficient time for equilibration of carbon dioxide tension between saline and the gastric lumen, anaerobic samples of the tonometer saline and of arterial blood were taken simultaneously and analyzed using standard pH and blood gas analyzers. pHi was calculated by a modification of the Henderson–Hasselbalch equation:

Where F is a time dependent factor for partly equilibrated samples provided by the manufacturer of the device.

Measurements

All patients had arterial catheters placed (arterial line kit, monitoring kit transpac® IV; Abbott, Sligo, Ireland) and central venous catheters via subclavian (Certofix trio V 720 7F × 8"; Braun, Melsungen, Germany). Arterial blood samples were simultaneously withdrawn for measurements of pH, oxygen and carbon dioxide tensions, and arterial oxygen saturation (Easy BloodGas; Medica, MA, USA). Central venous pressure, mean arterial pressure, heart rate and nasopharyngeal temperature were continuously monitored (Model 90308, SpaceLabs Inc., Redmond, WA, USA). All measurements were obtained at baseline (15 min before the start of the study) and again after the bolus infusion, and at 24 and 48 hours after the start of the continuous infusion. Platelets, leucocytes, bilirubin, alanine aminotransferase, and creatinine were determined at the same times (Vitalab Flexor, Dieren, The Netherlands).

TNF-α, IL-1β, IL-2 receptor, IL-6 and IL-8 levels were also measured, at the time points indicated above. Venous blood was collected into a 10 ml sterile plain tube (without anticoagulant) before administration of any medications and stored at -20°C. Before assay, all samples were thawed to room temperature and mixed by gentle swirling or inversion. All sera were assayed on the same day to avoid interassay variation. TNF-α, IL-1, IL-2 receptor, IL-6 and IL-8 levels were measured using a solid-phase, two-site chemiluminescent enzyme immunometric assay method (Immulite TNF-α, Immulite IL-1β, Immulite IL-2 receptor, IL-6 Immulite and IL-8 Immulite; EURO/DPC, Llanberis, UK). The antibodies used in this procedure have no known cross-reactivities with other cytokines. The lowest detectable limits of IL-1β, IL-2 receptor, IL-6, IL-8 and TNF-α were 1.5 pg/ml, 5 U/ml, 5 pg/ml, 2 pg/ml and 1.7 pg/ml, respectively.

The duration of mechanical ventilation was recorded. Survival was defined as being alive at hospital discharge.

Statistics

Repeated measures analysis of variance was used to evaluate the differences between and within groups. If significant differences were present then the groups were tested by independent samples t-tests to determine which difference was significant. Data are expressed as means ± standard deviation. P < 0.05 was considered statistically significant.

Results

Patient characteristics

The clinical and demographic characteristics of the NAC and control patients studied are summarized in Tables 1 and 2, respectively. Of the 53 patients, 27 received NAC (NAC group) and 26 received placebo (control group). Seventeen patients had septic shock on admission (seven in the NAC group, and 10 of the placebo-treated patients) and five died while in the ICU for reasons unrelated to infection (pulmonary embolism, cardiac death as determined by clinical and postmortem studies). Baseline Acute Physiology and Chronic Health Evaluation II scores (13.14 ± 3.79 and 15 ± 3.58 for the NAC and control groups, respectively) and Sepsis-related Organ Failure Assessment scores (5.62 ± 2.52 and 6.53 ± 2.2 for the NAC and control groups, respectively) were similar (P > 0.05). Infection was documented in all patients.
Table 1

Demographic and clinical characteristics of N-acetyl-L-cysteine treated patients

Patient

Age (years)

Sex

Type of infection

Pathogen

Outcome

1

86

F

Pneumonia

Pseudomomas aeruginosa

Survived

2

54

F

Pneumonia

Klebsiella pneumoniae 1

Died (MOF)

3

52

F

Pneumonia

Escherichia coli

Survived

4

52

F

Pneumonia

Staphylococcus aureus

Survived

5

67

M

Pneumonia

P. aeruginosa

Survived

6

37

M

Pneumonia

K. pneumoniae

Died (MOF)

7

39

M

Peritonitis

Enterococus faecalis

Survived

8

70

M

Peritonitis

S. aureus 1

Survived

9

90

M

Pneumonia

P. aeruginosa

Survived

10

45

F

Pneumonia

S. aureus

Survived

11

82

M

Pneumonia

E. faecalis 1

Died (PE)

12

70

M

Pneumonia

P. aeruginosa

Survived

13

82

M

Pneumonia

E. faecalis

Survived

14

65

F

Peritonitis

E. coli 1

Survived

15

80

M

Pneumonia

Streptococcus pneumoniae

Died (PE)

16

72

M

Pneumonia

P. aeruginosa 1

Survived

17

70

F

Pneumonia

E. faecalis

Survived

18

70

F

Peritonitis

S. aureus

Survived

19

70

M

Pneumonia

K. pneumoniae

Died (CD)

20

62

F

Pneumonia

S. aureus

Survived

21

55

M

Pneumonia

S. aureus 1

Survived

22

70

F

Peritonitis

E. coli 1

Survived

23

90

M

Pneumonia

E. faecalis

Died (MOF)

24

65

F

Pneumonia

E. coli 1

Survived

25

60

M

Pneumonia

S. pneumoniae

Died (MOF)

26

65

F

Pneumonia

E. faecalis 1

Survived

27

60

F

Peritonitis

E. faecalis, E. coli1

Survived

1Isolated from blood. CD, cardiac death; MOF, multiple organ failure; PE, pulmonary embolism.

Table 2

Demographic and clinical characteristics of control patients

Patient

Age (years)

Sex

Type of infection

Pathogen

Outcome

1

66

M

Pneumonia

Enterococcus faecalis

Died (MOF)

2

63

M

Pneumonia

Pseudomonas aeruginosa 1

Survived

3

67

M

Peritonitis

Staphylococcus aureus 1

Survived

4

80

M

Pneumonia

P. aeruginosa

Survived

5

81

M

Pneumonia

Escherichia coli

Died (MOF)

6

57

M

Pneumonia

E. coli

Survived

7

67

M

Peritonitis

E. faecalis 1

Survived

8

75

M

Pneumonia

Klebsiella pneumoniae 1

Died (PE)

9

67

M

Pneumonia

Staphylococus aureus

Survived

10

50

M

Peritonitis

E. faecalis 1

Survived

11

50

F

Pneumonia

S. aureus 1

Survived

12

78

M

Pneumonia

K. pneumoniae

Survived

13

65

M

Pneumonia

E. faecalis

Survived

14

50

M

Peritonitis

S. aureus 1

Died (MOF)

15

63

M

Pneumonia

S. pneumoniae 1

Died (CD)

16

45

F

Pneumonia

S. pneumoniae

Survived

17

67

M

Peritonitis

E. coli 1

Survived

18

91

K

Pneumonia

S. aureus

Survived

19

30

M

Peritonitis

E. faecalis 1

Survived

20

59

M

Pneumonia

S. pneumoniae

Died (MOF)

21

69

M

Pneumonia

S. pneumoniae

Survived

22

71

M

Peritonitis

S. aureus 1

Survived

23

58

M

Pneumonia

E. coli 1

Died (MOF)

24

46

F

Peritonitis

E. faecalis 1

Survived

25

66

M

Pneumonia

E. faecalis, E. coli

Survived

26

71

M

Pneumonia

K. pneumoniae

Died (MOF)

1Isolated from blood. CD, cardiac death; MOF, multiple organ failure; PE, pulmonary embolism. [AU: for patient number 9, please define 'Sf' in the pathogen column.]

Haemodynamic parameters and oxygen transport variables

There were no significant differences between the groups with respect to pH, oxygen tension, carbon dioxide tension, arterial oxygen tension/fractional inspired oxygen ratio and arterial oxygen saturation (P > 0.05). No significant change in mean arterial pressure or heart rate was found in either group (Table 3). Also, there were no significant differences between the groups in biochemical parameters (P > 0.05).
Table 3

Hemodynamic, oxygen and temperature variables

Variable

Baseline

Immediately after NAC infusion

24 hours after NAC infusion

48 hours after NAC infusion

Heart rate (beats/min)

   NAC

110.88 ± 25.9

113.00 ± 25.4

112.74 ± 22.4

108.70 ± 22.2

   Control

104.84 ± 18.2

105.19 ± 23.5

105.23 ± 23.5

103.15 ± 22.7

Mean arterial pressure (mmHg)

   NAC

90.85 ± 16.67

88.92 ± 13.01

86.07 ± 13.21

85.96 ± 13.41

   Control

91.26 ± 18.25

83.80 ± 14.77

85.42 ± 13.42

83.80 ± 11.31

Arterial pH

   NAC

7.34 ± 0.10

7.41 ± 0.07

7.38 ± 0.10

7.39 ± 0.06

   Control

7.35 ± 0.09

7.38 ± 0.07

7.39 ± 0.08

7.36 ± 0.08

Arterial carbon dioxide tension (mmHg)

   NAC

35.88 ± 12.7

34.62 ± 18.8

35.00 ± 14.2

38.54 ± 15.1

   Control

31.69 ± 20.1

38.56 ± 20.2

36.46 ± 71.13

34.33 ± 21.6

Arterial oxygen tension/fractional inspired oxygen ratio (mmHg)

   NAC

172 ± 88

176 ± 76

178 ± 81

179 ± 126

   Control

174 ± 76

177 ± 65

181 ± 70

179 ± 68

Arterial oxygen saturation (%)

   NAC

96.1 ± 3.4

95.1 ± 3.7

95.2 ± 3.8

95.6 ± 4.2

   Control

95.9 ± 3.5

95.0 ± 4.1

94.8 ± 3.2

95.1 ± 3.6

Temperature (°C)

   NAC

36.8 ± 0.75

37 ± 0.78

36.8 ± 0.75

36.9 ± 0.48

   Control

36.6 ± 0.57

36.8 ± 0.45

36.6 ± 0.57

36.8 ± 0.53

Data are expressed as mean ± standard deviation. We identified no statistically significant differences between groups. NAC, N-acetyl-L-cysteine.

Outcome

Outcomes are listed in Tables 1 and 2. The overall hospital mortality was 26% (seven patients) in the NAC group and 31% (eight patients) in the group control (P > 0.05). All of the patients who died did so while they were being mechanically ventilated. In the NAC and placebo groups, the durations of mechanical ventilation were 8 ± 2 and 8 ± 3 days, respectively (P > 0.05), and the numbers of ventilator-free days were 9 ± 3 and 8 ± 3, respectively (P > 0.05). The length of ICU stay of NAC-treated survivors was not significantly different from that of placebo-treated survivors (10 ± 2 days versus 11 ± 4 days; P > 0.05).

Plasma cytokine levels

TNF-α, IL-1β, IL-2 receptor, IL-6 and IL-8 levels remained unchanged during the study (Table 4).
Table 4

APACHE II and SOFA scores, cytokine levels, gastric intramucosal pH and gastric intramucosal carbon dioxide tension

Variable

Baseline

Immediately after NAC infusion

24 hours after NAC infusion

48 hours after NAC infusion

APACHE II score

   NAC

13.14 ± 3.79

-

13.33 ± 3.83

12.74 ± 3.87

   Control

15 ± 3.58

-

15.34 ± 3.30

15.69 ± 3.4

SOFA score

   NAC

5.62 ± 2.52

5.55 ± 2.04

5.48 ± 2.57

5.48 ± 2.7

   Control

6.53 ± 2.2

6.92 ± 2.59

7.15 ± 2.9

7.15 ± 2.86

Tumour necrosis factor-α (pg/ml)

   NAC

25.58 ± 15.8

26.02 ± 16.1

22.68 ± 13.9

28.17 ± 26.8

   Control

22.57 ± 28.2

24.90 ± 13.56

25.05 ± 21.8

28.25 ± 24.3

IL-1β (pg/ml)

   NAC

6.68 ± 1.85

6.38 ± 1.07

5.91 ± 1.26

5.57 ± 1.62

   Control

5.35 ± 1.32

5.09 ± 0.30

5.34 ± 1.01

5.11 ± 0.58

IL-2 receptor (U/ml)

   NAC

1847 ± 1366

1918 ± 1450

1829 ± 1427

1816 ± 1806

   Control

2288 ± 1503

2372 ± 1531

2382 ± 1599

2168 ± 843

IL-6 (pg/ml)

   NAC

100.26 ± 88

100.22 ± 19.8

110.51 ± 37

100.38 ± 38

   Control

115.85 ± 85

115.64 ± 19.8

113.86 ± 27

119.48 ± 38

IL-8 (pg/ml)

   NAC

161.50 ± 55

161.6 ± 10.3

162.1 ± 12.4

168.8 ± 113

   Control

172.95 ± 27

163.3 ± 28.4

169.6 ± 28.6

171.0 ± 31

Gastric intramucosal pH

   NAC

8.41 ± 0.21

8.43 ± 0.22

8.43 ± 0.17

-

   Control

8.26 ± 0.18

8.31 ± 0.16

7.45 ± 0.47

-

Gastric intramucosal carbon dioxide tension (mmHg)

   NAC

67.2 ± 20.1

70.2 ± 15.6

69.0 ± 21.9

-

   Control

68.7 ± 22.8

69.7 ± 23

68.9 ± 25.7

-

Data are expressed as means ± standard deviation. APACHE, Acute Physiology and Chronic Health Evaluation; IL, interleukin; NAC, N-acetyl-L-cysteine; SOFA, Sepsis-related Organ Failure Assessment.

Gastric intramucosal pH

There was no significant difference between the groups with respect to pHi (P > 0.05; Table 4).

Side effects

The NAC infusion was well tolerated by all patients who received it, and no side effects were noted during or after administration of NAC.

Discussion

Systemic inflammatory response leading to postoperative organ dysfunction and sepsis remains a formidable clinical challenge and carries a significant risk for death. Recent clinical studies suggest that patients with sepsis undergo relative oxidative stress [12]. Overwhelming production of oxygen free radicals is thought to play a central role in the inflammatory process [3]. Many investigators have suggested that use of exogenous agents such as NAC may be of benefit in preventing oxygen free radical damage in patients suffering from septic shock [13, 14]. NAC acts as a powerful oxygen free radical scavenger, and it replenishes depleted glutathione stores, thus enhancing defence against endogenous antioxidants [15].

Sepsis and septic shock remain major causes of death in ICUs. Complications of sepsis result from an intense host response caused by a disturbance of the delicate equilibrium between various proinflammatory and anti-inflammatory mediators [16]. Overwhelming production of proinflammatory cytokines such as TNF-α, IL-1β, IL-2 receptor, IL-6 and IL-8 may induce biochemical and cellular alterations either directly or by orchestrating secondary inflammatory pathways. NAC can also exert important anti-inflammatory effects on neutrophills and monocytes [17]. Zhang and coworkers [13] found that this decreased inflammatory response was reflected by complete inhibition of TNF release with pretreatment NAC. Peristeris and coworkers [6] demonstrated that pretreatment with NAC significantly inhibited TNF production both in serum and in spleen in a mouse model of endotoxaemia. This attenuating effect of NAC on TNF production is most likely due to decreased release of oxygen free radicals. Furthermore, in patients with sepsis who were administered NAC, Paterson and coworkers [18] found decreased nuclear factor-κB activation, which was associated with decreased levels of IL-8 but not of IL-6 or soluble intercellular adhesion molecule-1. That pilot study suggested that NAC may blunt the inflammatory response to sepsis by interfering with nuclear factor-κB activation.

Spapen and colleagues [19] found that NAC had no significant effect on plasma TNF, IL-6 or IL-10 levels, but acutely decreased IL-8 and soluble TNF receptor/p55 levels. They demonstrated that the attenuated production of IL-8 – a potential mediator of septic lung injury – might have contributed to the lung protective effects of NAC.

In contrast to the findings of those studies, in the present study we found that NAC infusion did not affect cytokine levels in patients with severe sepsis. Cytokine levels in plasma do not necessarily reflect local synthesis of cytokines by cells. Many cells have surface receptors for these cytokines, with high binding properties, and target cells and soluble receptors can trap cytokines. Thus cytokines released locally may remain undetected in plasma. In the present study we found that plasma cytokine levels remained unchanged over a period of 48 hours. Spapen and coworkers [19] found that a short-term (4 hour) infusion of NAC in patients with early diagnosed septic shock improved systemic oxygenation and static lung compliance without influencing systemic and pulmonary haemodynamics, and NAC-treated survivors had a less complicated weaning period and a shorter length of stay in the ICU than did the placebo-treated group. Spies and coworkers [14] documented improvements in cardiac function, tissue oxygenation and survival in patients in whom NAC (150 mg/kg intravenous bolus, followed by 18.75 mg over 90 min) increased oxygen consumption. NAC improved lung compliance, chest radiographic oedema score, and arterial oxygenation in patients with acute respiratory distress syndrome (ARDS) [20]. Recently, prolonged infusion of NAC (70 mg/kg for 10 days) was found to improve cardiac function and to attenuate lung injury in patients with ARDS [21].

Despite these encouraging findings, the role of NAC in critically ill remains controversial. Recent randomized, placebo-controlled studies found no significant differences between NAC and placebo in gas exchange, development of ARDS, and mortality in patients with ARDS and early septic shock [22, 23]. Furthermore, several papers reported conflicting and undesirable effects of NAC administration. For example, Peake and coworkers [24] treated patients with a different NAC infusion scheme (150 mg/kg intravenous bolus, followed by 50 mg/kg over 4 hours, and then 100 mg/kg per 24 hours for 44 hours) and found significant depression of cardiovasculer performance after 24 hours, together with increased mortality. In the present study we found that NAC infusion had no effect on the cardiovascular and pulmonary systems in patients with severe sepsis. However, the study was designed to assess the effects of NAC treatment given before septic shock but after the development of the systemic inflammatory response syndrome. For this reason no serious cardiovascular and pulmonary system problems were encountered in the patients studied.

Oxygen radical scavengers, administered before or at the onset of sepsis, were shown to improve survival in animal models of sepsis [25]. NAC was shown to enhance oxygen consumption via increased oxygen extraction in patients 18 hours after the onset of fulminant liver failure [26]. Spies and coworkers [14] demostrated that NAC provided a transient improvement in tissue oxygenation in about half of a group of patients with septic shock, and they identified increased whole body oxygen consumption and pHi, and decreased veno-arterial carbon dioxide tension. Those investigators also found a higher survival rate in NAC responders, and half of the patients receiving NAC did not respond; they suggested that, in some patients, sepsis irreversibly damages the microvasculature, which would account for the lack of effect of NAC in some patients. In the present study, we found that NAC infusion did not affect pHi in severe sepsis in humans.

In the present study we identified no positive effects of NAC. We were unable to detect differences in systemic oxygenation, ventilatory requirements, or mortality rate in NAC-treated patients, as reported by Szakmany and coworkers [22] and by Domenighetti and colleagues [23]. We also found that NAC infusion did not affect biochemical parameters in patients with severe sepsis, as reported by Szakmany and coworkers [22].

Vomiting and diarrhoea are the side effects most commonly experienced with NAC. Other reported side effects include increased blood pressure, chest pain, hypotension, rectal bleeding, respiratory distress, headache, lethargy, fever and skin allergy [27]. We did not encounter these side effects in the present study.

We found that NAC infusion (150 mg/kg intravenous bolus, followed by intravenous infusion at 12.5 mg/kg per hour for 6 hours) did not affect cytokine levels, patient outcomes, or pHi in severe sepsis in humans. From the literature it appears that lower doses of NAC are associated with favourable haemodynamic but no immunomodulatory effects [14] whereas higher doses do influence cytokine production but may cause cardiovascular dysfunction [13, 19, 24]. Because of the limited number of patients included and the short period of observation, our findings require confirmation in larger clinical trials of NAC infused in a dose-titrated manner. However, our findings do not support the use of NAC in patients with severe sepsis.

Key messages

NAC administration had no statistically significant effects on serum cytokine levels and pHi. We identified no adverse effects assoaicted with infusion of NAC.

On the basis of our findings, there appears to be no role for NAC in patients with severe sepsis.

Notes

Abbreviations

ARDS: 

acute respiratory distress syndrome

ICU: 

intensive care unit

IL: 

interleukin

NAC: 

N-acetyl-L-cystein

pHi: 

gastric intramucosal pH

TNF: 

tumour necrosis factor.

Authors’ Affiliations

(1)
Department of Anaesthesiology, Reanimation, Medical Faculty, Trakya University, Edirne, Turkey
(2)
Associate Professor, Department of Anaesthesiology, Reanimation, Medical Faculty, Trakya University, Edirne, Turkey
(3)
Professor, Chair of Department of Anaesthesiology, Reanimation, Medical Faculty, Trakya University, Edirne, Turkey

References

  1. Bone RC: Gram-negative sepsis: a dilemma of modern medicine. Clin Microbial Rev 1993, 6: 57-68.Google Scholar
  2. Members of The American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20: 864-874.View ArticleGoogle Scholar
  3. Goode HF, Cowley HC, Walker BE, Webster NR: Decreased antioxidant status and icreased lipid peroxidation in patients with sepsis and secondary organ dysfunction. Crit Care Med 1995, 23: 646-651. 10.1097/00003246-199504000-00011View ArticlePubMedGoogle Scholar
  4. Galley HF, Davies MJ, Webster NR: Ascorbyl radical formation in patients with sepsis: effect of ascorbate loading. Free Rad Biol Med 1995, 20: 139-143. 10.1016/0891-5849(95)02022-5View ArticleGoogle Scholar
  5. Flanagan RJ, Meredith TJ: Use of N-acetyl cysteine in clinical toxicology. Am J Med 1991, Suppl 3C: 131S-139S. 10.1016/0002-9343(91)90296-AView ArticleGoogle Scholar
  6. Peristeris P, Clark BD, Gatti S, Faggioni R, Mantovani A, Mengozzi M, Orencole SF, Sironi M, Ghezzi P: N-acetylcysteine and glutathione as inhibitors of tumor necrosis factor production. Cell Immunol 1992, 140: 390-399.View ArticlePubMedGoogle Scholar
  7. Keays R, Harrison PM, Wendon JA, Forbes A, Gove C, Alexander GJ, Williams R: Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: A prospective trial. BMJ 1991, 30: 1026-1029.View ArticleGoogle Scholar
  8. Ortolani O, Conti A, De Gaudio AR, Moraldi E, Cantini Q, Novelli G: The effect of glutathione and N-acetylcysteine on lipoperoxidative damage in patients with early septic shock. Am J Respir Crit Care Med 2000, 161: 1907-1911.View ArticlePubMedGoogle Scholar
  9. Doglio GR, Pusajo JF, Egurrola MA, Bonfigli GC, Parra C, Vetere L, Hernandez MS, Fernandez S, Palizas F, Gutierrez G: Gastric mucosal pH as a prognostic index of mortality in critically ill patients. Crit Care Med 1991, 19: 1037-1041.View ArticlePubMedGoogle Scholar
  10. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II:a severity of disease classification system. Crit Care Med 1985, 13: 818-829.View ArticlePubMedGoogle Scholar
  11. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG: The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996, 22: 707-710. 10.1007/s001340050156View ArticlePubMedGoogle Scholar
  12. Ogilvie AC, Groeneveld ABJ, Straub JP, Thijs LG: Plasma lipid peroxides and antioxidants in human septic shock. Intensive Care Med 1991, 17: 40-44.View ArticlePubMedGoogle Scholar
  13. Zhang H, Spapen H, Nguyen DN, Benlabed M, Buurman WA, Vincent JL: Protective effects of N-acetyl-L-cysteine in endotoxemia. Am J Physiol 1994, 266: H1746-1754.PubMedGoogle Scholar
  14. Spies CD, Reinhart K, Witt I, Meier-Hellmann A, Hannemann L, Bredle DL, Schaffartzik W: Influence of N-acetyl-cysteine on indirect indicators of tissue oxygenation in septic shock patients: results from a prospective, randomized, double-blind study. Crit Care Med 1994, 22: 1738-1746.View ArticlePubMedGoogle Scholar
  15. Repine JE: Scientific perspectives on adult respiratory distress syndrome. Lancet 1992, 339: 466-469. 10.1016/0140-6736(92)91067-IView ArticlePubMedGoogle Scholar
  16. Marsh CB, Wewers MD: The pathogenesis of sepsis: factors that modulate the response to gram-negative bacterial infection. Clin Chest Med 1996, 17: 183-197.View ArticlePubMedGoogle Scholar
  17. Hashimato S, Gon Y, Matsumoto K, Takeshita I, Horie T: N-acetylcysteine attenuates TNF-alpha-induced p38 MAP kinase and p38 MAP kinase-mediated IL-8 production by human pulmonary vasculer endothelial cells. Br J Pharmacol 2001, 132: 270-276.View ArticleGoogle Scholar
  18. Paterson RL, Galley HF, Webster NR: The effect of N-acetylcysteine on nuclear factor-kappa B activation, interleukin-6, interleukin-8, and intercellular adhesion molecule-1 expression in patients with sepsis. Crit Care Med 2003, 31: 2574-2578.View ArticlePubMedGoogle Scholar
  19. Spapen H, Zhang H, Demanet C, Vleminckx W, Vincent JL, Huyghens L: Does N-acetyl-L-cysteine influence cytokine response during early human septic shock? Chest 1998, 113: 1616-1624.View ArticlePubMedGoogle Scholar
  20. Suter PM, Domenighetti G, Schaller MD, Laverriere MC, Ritz R, Perret C: N-acetyl cysteine enhances recovery from acute lung injury in man: a randomized, double-blind, placebo-controlled clinical study. Chest 1994, 105: 190-194.View ArticlePubMedGoogle Scholar
  21. Bernard GR, Wheeler AP, Arons MM, Morris PE, Paz HL, Russell JA, Wright PE: A trial of antioxidants N-acetylcysteine and procysteine in ARDS. Chest 1997, 112: 164-172.View ArticlePubMedGoogle Scholar
  22. Szakmany T, Marton S, Molnar Z: Lack of effect of prophylactic N-acetylcysteine on postoperative organ dysfunction following major abdominal tumour surgery: a randomised placebo-controlled, double-blinded clinical trial. Anaesth Intensive Care 2003, 31: 267-271.PubMedGoogle Scholar
  23. Domenighetti G, Suter PM, Schaller MD, Ritz R, Perret C: Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomised placebo-controlled, double-blinded clinical trial. J Crit Care 1997, 12: 177-182. 10.1016/S0883-9441(97)90029-0View ArticlePubMedGoogle Scholar
  24. Peake SL, Moran JL, Leppard PI: N-acetyl-L-cysteine depresses cardiac performance in patients with septic shock. Crit Care Med 1996, 24: 1302-1310. 10.1097/00003246-199608000-00006View ArticlePubMedGoogle Scholar
  25. Powell RJ, Machiedo GW, Rush BF Jr, Dikdan GS: Effect of oxygen free radical scavengers on survival in sepsis. Am Surg 1991, 57: 86-88.PubMedGoogle Scholar
  26. Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R: Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 1991, 324: 1852-1857.View ArticlePubMedGoogle Scholar
  27. Holdiness MR: Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet 1991, 20: 123-134.View ArticlePubMedGoogle Scholar

Copyright

© Emet et al.; licensee BioMed Central Ltd. 2004

This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Advertisement